Bullish & Foolish
Full NDRA fundamentals All 466 on the Survival Watch

NDRAENDRA LIFE SCIENCES INC.

Is Endra Life Sciences struggling financially?

Yes, by its own account. Endra Life Sciences told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$6.7M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 3months

    If the burn speeds up

    Empty by Sep 2026

  • 5months

    If it eases off

    Empty by Nov 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$1.7M

÷

Cash burned over the last 12 months

$5.2M

What Endra Life Sciences told the SEC

…) as of March 31, 2026. The Company has not established an ongoing source of revenue sufficient to cover its operating costs and to allow it to continue as a going concern and will require additional financing to fund its future planned operations, including research and development and commercialization of its products. These matters raise substantial doubt about the Company’s ability to continue as going concern. The accompanying financial statements for the three months ended March 31, 2026 have been prepared assuming the Company…

ENDRA LIFE SCIENCES INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 98.0% share-count increase The company issued stock. Each share now owns 49.5% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 53% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt